A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients
Description:
Here, Freis's team studied the effectiveness of pentapyrrolidinium (a ganglionic-blocking agent, also called pentolinium) as an antihypertensive treatment. They concluded that the drug had several advantages in the treatment of severe hypertension over another ganglionic-blocking agent, hexamethonium. The drug's attributes, longer duration of action, greater potency, and a more uniform response to oral administration, more than compensated for its side effects and the frequent need to adjust dosage.
Number of Image Pages:
7 (954,891 Bytes)
Date:
1954-04 (April 1954)
Creator:
Freis, Edward D.
Partenope, Edward A.
Lilienfield, Lawrence S.
Rose, John C.
Source:
Periodical: Freis, Edward D., Edward A. Partenope, Lawrence S. Lilienfield, and John C. Rose. "A Clinical Appraisal of Pentapyrrolidinium (M&B 2050) in Hypertensive Patients." Circulation IX, 4 (April 1954): 540-546. Article.
Publisher:
[American Heart Association]
Rights:
This item is in the public domain. It may be used without permission.
Subject:
Medical Subject Headings (MeSH):
Hypertension
Antihypertensive Agents
Hexamethonium
Pentolinium Tartrate
Exhibit Category:
The Veterans Administration Hospital and Georgetown University School of Medicine, 1949-1964
